Physician profile
Ali K Mossaid
NPI 1316508278
$6,323.79
in general payments reported to CMS, 2019-2025
27 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $199 · 2023: $944 · 2024: $2,587 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,105 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,104.65 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,057.94 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $838.03 | 2024-2025 | |
| Lilly USA, LLC | $762.03 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $561.62 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $523.50 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.80 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $404.21 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $258.89 | 2023-2025 | Quviviq, Quviviq |
| Exact Sciences Corporation | $254.38 | 2024-2025 | Cologuard Collection Kit |
| Ardelyx, INC. | $208.27 | 2024-2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $175.71 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $108.58 | 2023-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Shield Therapeutics INC | $106.29 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $100.56 | 2024 | Tavalisse, Rezlidhia |
| E.R. Squibb & Sons, L.L.C. | $95.48 | 2022-2025 | Eliquis, Opdivo, Camzyos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $76.28 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $74.02 | 2024-2025 | Spravato |
| Abbott Laboratories | $47.88 | 2025 | Freestyle Libre 3 |
| Viatris Specialty LLC | $44.36 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $43.19 | 2025 | Auvelity |
| Amgen INC. | $32.02 | 2024 | Otezla, Repatha |
| Inspire Medical Systems, INC. | $26.79 | 2025 | Inspire |
| Mylan Specialty L.P. | $23.83 | 2024 | Yupelri |
| Verona Pharma, INC. | $20.52 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Janssen Biotech, INC. | $18.01 | 2024 | Darzalex, Talvey, Tecvayli |
| Kowa Pharmaceuticals America, INC. | $13.38 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Mossaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.